First-line PARP inhibitors in ovarian cancer: summary of an <i>ESMO Open - Cancer Horizons</i> round-table discussion.

ESMO Open · 2020 · PMC7783599 · PMID 33310779

Europe PMC DOI

hedged sentence

0.0540

closest p · 1.1× alpha

0.0540

boldest claim

The sentences

did not reach statistical significancep=0.054so close (0.05 < p ≤ 0.1)

The median OS improved by 12.9 months with maintenance olaparib compared with placebo; however, this did not reach statistical significance (HR 0.74, 95% CI 0.54 to 1.00; p=0.054).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.